



PRC Meeting

Wednesday, March 8, 2023

9:30 AM to 12:00 PM

****The Committee does not anticipate a need for a closed session during this meeting****

****VIRTUAL / IN-PERSON HYBRID****

Meeting called by:	Dr. Timothy Chizmar
Type of meeting:	Protocol Review Committee

PRC Agenda Items		
Call to order		Dr. Chizmar
Approval of minutes	January 11, 2023 Minutes	
Announcements		
Old Business		
New Business	IV Droperidol for Nausea	Dr. Sward and Erich Goetz, NRP
Journal Club		
Discussion(s)	BLS Supraglottic Airways Consult Requirements for Use of Atropine in Treating Unstable High-grade Blocks	Dr. Chizmar Dr. Stone
Adjournment		Dr. Chizmar
Next Meeting	May 10, 2023 9:30am-12:00pm	



Protocol Review Committee Meeting Minutes

November 9, 2022

Attendance:

Committee Members in Attendance (In-person/Virtual): Mary Alice Vanhoy, Tyler Stroh, Dr. Steven White, David Chisholm, Marianne Warehime, Rachel Itzoe, Mark Buchholtz, James Gannon, Dr. Kevin Pearl, Dr. Thomas Chiccone, Dr. Roger Stone, Dr. Janelle Martin, Dr. Jeffrey Fillmore, Dr. Timothy Chizmar (Chair), Meg Stein (Protocol Administrator)

Guests: Terrell Buckson, Dr. Doug Floccare, Erich Goetz, Jeanie Hannas, Michael Herndon, Ben Kaufman, Dr. Kashyap Kaul, Dr. Stephanie Kemp, Jon Krohmer, Mitchell Lewis, Jr., Dr. Asa Margolis, Melissa Meyers, Dr. Kevin Seaman, Dr. Jeffrey Uribe, Scott Legore

Excused: Kathleen Grote, Dr. Jennifer Anders

Alternates: Tim Burns

Absent: Mary Beachley, Christian Griffin, Melissa Fox, Gary Rains, Dr. Matthew Levy, Dr. Jennifer Guyther

Meeting called to order at 9:33 a.m. by Dr. Chizmar.

Minutes: A motion was made by Dr. Chiccone and seconded by Marianne Warehime to approve the minutes as written. The motion passed without objections or abstentions.

Announcements:

Old Business:

New Business:

IV Droperidol for Nausea – Presented by Erich Goetz, NRP: A proposal to use IV droperidol as an alternative or in conjunction with Zofran in the treatment of nausea and vomiting was presented by Paramedic Goetz. Droperidol is already in the Maryland ALS formulary and has been shown to be effective for treatment of nausea and vomiting in other settings.

Discussion points included:

- Concerns about giving Zofran and droperidol combined rather than separately. It was clarified that sequential rather than combined dosing was the intent of the proposal.
- Droperidol appears to be better than Zofran for treating cannabinoid induced hyperemesis and migraines.
- Guidance on when to switch from Zofran to droperidol or vice versa including dosage to be administered and whether this should be a single dose or whether repeat doses should be allowed.
- Questions were raised about possible contraindications for pediatric and pregnant patients.
- Concerns were raised about the risks of QT prolongation with anti-emetics. The possible need for clinicians to obtain 12-lead ECGs when administering multiple doses and whether this would lead to a need for cardiac monitoring in the ED were discussed.
- A possible requirement for medical consultation for repeat doses was discussed.



Protocol Review Committee Meeting Minutes

November 9, 2022

After extended discussion, it was agreed have the authors bring a revised proposal back to the May 2023 Meeting. PEMAC will be consulted regarding the question of use for pediatric and pregnant patients.

Journal Club:

Discussions:

BLS Supraglottic Airways – Presented by Dr. Chizmar: Dr. Chizmar discussed an option that has previously been mentioned for making supraglottic airways (SGAs) a BLS skill.

Discussion points included:

- Existing deficiencies in BVM skills and whether improving BVM should be addressed prior to adding SGAs. It was also noted that SGAs often make bagging easier and more effective.
- Need for extensive training prior to adding SGA as a BLS skill was discussed.
- The possibility of making SGA an Optional Supplemental Protocol (OSP) for BLS was discussed. Some jurisdictions would have a greater need for BLS SGAs due to ALS availability. On the other hand, objection was raised to adding it as an OSP if there is a true need for the skill.

It was agreed to continue this discussion at a future date.

Consult Requirements for Use of Atropine in Treating High-grade Blocks – Presented by Dr.

Stone: Dr. Stone pointed out the need for clarification in the Adult Bradycardia Algorithm regarding pacing versus atropine for symptomatic bradycardia with hypotension. Some feel that the wording implies that atropine is an equal option to transcutaneous pacing (TCP) in these situations when in reality TCP should be the first-line treatment.

Discussion points included:

- Requirement of a consult for use of atropine prior to TCP or removal of atropine from the algorithm, especially with regard to high-grade blocks.
- There are certain situation when atropine does work on high-grade blocks so there is an argument for leaving it in the algorithm.

A proposal was made to add a statement to administer atropine if TCP is ineffective or unavailable and to eliminate the footnote regarding a requirement for a medical consultation prior to administration of atropine for high-grade blocks in the 2023 Protocols. Dr. Chizmar called for any objections. With no objections raised, these changes will be added to the 2023 Protocols.

Albuterol Shortage: Dr. Chizmar advised that he is looking for options for jurisdictions that are running low on albuterol. Alternatives discussed were terbutaline and levalbuterol. MDI albuterol was also mentioned but is also in limited supply. Dr. Chizmar advised that a memo would be coming out with options for affected jurisdictions. He also asks that jurisdictions keep him informed of shortages and which option is being used.

Good of the Order:

Adjournment: A motion was made by Mary Alice Vanhoy and seconded by Tyler Stroh to adjourn. Without objection, the meeting was adjourned at 11:43 a.m.